Amedisys (AMED) PT Cut to $47 at Mizuho Following Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Mizuho Securities Upgrades Amedisys (AMED) to Buy; Sell-Off Excessive
November 7, 2016 7:48 AM ESTMizuho Securities upgraded Amedisys (NASDAQ: AMED) from Neutral to Buy with a price target of $47.00, calling the sell-off after the COO resigned 'excessively overdone'.
Analyst Sheryl Skolnick commented, "AMED's shares dove Friday in concert with another C-Suite change at the... More
Amedisys (AMED) Taps Kindred Healthcare's Gerard as COO
November 4, 2016 6:33 AM EDTAmedisys, Inc. (Nasdaq: AMED) announced that industry leader Christopher Gerard will join the Company as Chief Operating Officer (COO) on January 3, 2017. Daniel McCoy will remain in this role until January 3, 2017.
Gerard brings more than 20 years of home health and hospice experience to the Company. In his new role, Gerard will be responsible for the Amedisys home health, hospice and personal care operations.
Chris has built an impressive track record of strategic, operational and financial accomplishments over the past two decades, said Amedisys President and Chief Executive Officer Paul... More
Amedisys (AMED) Misses Q3 EPS by 8c
November 3, 2016 5:03 PM EDTAmedisys (NASDAQ: AMED) reported Q3 EPS of $0.36, $0.08 worse than the analyst estimate of $0.44. Revenue for the quarter came in at $361.6 million versus the consensus estimate of $361.08 million.
For earnings history and earnings-related data on Amedisys (AMED) click here.
... More